We previously described a negative allosteric modulator (NAM) of FSHR (ADX61623) that blocked FSH-induced cAMP and progesterone production but did not block estradiol production. That FSHR NAM did not affect FSH-induced preovulatory follicle development as evidenced by the lack of an effect on the number of FSH-dependent oocytes found in the ampullae following ovulation with hCG. A goal is the development of a nonsteroidal contraceptive. Toward this end, a highthroughput screen using human FSHR identified an additional nonsteroidal small molecule (ADX68692). Although ADX68692 behaved like ADX61623 in inhibiting production of cAMP and progesterone, it also inhibited FSH-induced estradiol in an in vitro rat granulosa primary cell culture bioassay. When immature, noncycling female rats were injected subcutaneously or by oral dosing prior to exogenous FSH administration, it was found that ADX68692 decreased the number of oocytes recovered from the ampullae. The estrous cycles of mature female rats were disrupted by administration by oral gavage of 25 mg/kg and 10 mg/kg ADX68692. In the highest dose tested (25 mg/kg), 55% of animals cohabited with mature males had implantation sites compared to 33% in the 10 mg/kg group and 77% in the control group. A surprising finding was that a structural analog ADX68693, while effectively blocking progesterone production with similar efficacy as ADX68692, did not block estrogen production and despite better oral availability did not decrease the number of oocytes found in the ampullae even when used at 100 mg/kg. These data demonstrate that because of biased antagonism of the FSHR, nonsteroidal contraception requires that both arms of the FSHR steroidogenic pathway must be effectively blocked, particularly estrogen biosynthesis. Thus, a corollary to these findings is that it seems reasonable to propose that the estrogen-dependent diseases such as endometriosis may benefit from inhibition of FSH action at the ovary using the FSHR NAM approach.
INTRODUCTION
The control of fertility is a major public health issue [1, 2] . FSH receptor (FSHR) antagonists could potentially represent a novel nonsteroidal approach for contraception due to their specific action on ovarian tissue without affecting peripheral and central tissues. For example, FSHb gene knockout female mice are infertile because of a block in folliculogenesis [3] . Likewise, women with resistant ovary syndrome due to nonfunctional FSHRs are infertile [4] , and female mice null for the FSHR gene are infertile [5, 6] , reinforcing the hypothesis that an antagonist of FSHR would act to limit proliferation of follicular granulosa cells in the ovary, therefore acting as a contraceptive. Small molecules that have FSHR agonist or antagonist activities are likely interacting with the transmembrane (TM) domains, not the extracellular domain [7, 8] . However, some small molecule antagonists have been shown to inhibit FSH binding [9] , and yet other FSHR antagonists do not compete for FSH binding with the latter being considered as negative allosteric modulators (NAM) [10] .
FSHR is a complex membrane-bound G protein-coupled receptor (GPCR) [11, 12] . It is synthesized as an unusually large extracellular domain of 365 amino acids and three carbohydrate attachment sites and a predicted rhodopsinlike TM domain structure of roughly an additional 330 amino acids. Its ligand, FSH, is equally complex, made up of two dissimilar subunits and decorated with three or four carbohydrate chains [13] . The crystal structure of human FSH (hFSH) [13] and of the human FSHR (hFSHR) extracellular domain in complex with FSH has revealed key residues that are essential for highaffinity interaction between FSH and its receptor [14, 15] .
As a GPCR, the canonical postligand-binding action of FSHR is as an upstream guanine nucleotide exchange factor for G proteins where the G proteins are the effector molecules of activation of the adenylate cyclase ! cAMP ! protein kinase A (PKA) pathway. Cyclic AMP binds to the regulatory subunit of PKA, causing it to dissociate, allowing the catalytic subunit to be fully functional as a kinase. Kinase phosphorylation can be inhibitory as well as stimulatory and can result in feedforward transduction even in the former case. For example, FSH can induce an increase in cAMP, resulting in the activation of PKA that in turn can phosphorylate and inactivate a protein phosphatase that dephosphorylates extracellular regulated kinase (ERK1/2) (also known as mitogen activated protein kinase, or MAPK). Removing the constitutive dephosphorylation of ERK1/2 allows for phosphorylated ERK1/2 to accumulate with downstream effects of activating c-fos, c-myc, and CREB. Thus, FSH can regulate cell proliferation and differentiated functions through these pathways [11, [16] [17] [18] [19] . In addition, FSH can exert its effects via cAMP binding to exchange proteins that are activated by cAMP (EPAC) [20] [21] [22] . Depending upon their relative abundance, distribution, and localization, as well as the specific cellular environments, EPAC and PKA may act independently, converge synergistically, or oppose each other in regulating a specific cellular function, providing a mechanism (a so-called grid) for a more precise and integrated control of the cAMP-signaling pathways in a spatial and temporal manner [23] .
We recently reported an FSHR NAM, ADX61623, which blocked FSH-induced cAMP and progesterone production, but did not block FSH-induced estradiol production. This observation demonstrated that FSHR is capable of biased signaling and that ADX61623 is a biased antagonist [24] . Those findings are complemented by recent work showing that FSHR, when bound to the adaptor protein b-arrestin (which binds to the intracellular loops of the FSHR), signals via alternate pathways that are independent of G proteins [25] as has been shown for some other GPCRs [26] . Our working model is that beyond the initial burst of cAMP induced by FSH, the FSHR signalosome then can be viewed as a switch that is capable of turning parts of the signaling grid off and on. It seems reasonable to suggest that FSHR intracellular loop accessibility modified by allosteric changes in the TM domains caused by ligand binding is involved in the initiation and regulation of signaling pathways [27] . In fact recent studies demonstrate that a G-protein biased agonist can stabilize a conformation that is distinct from that stabilized by an arrestin-biased agonist [28, 29] . FSHR NAM ADX61623 was not able to block FSHdependent preovulatory follicle development as evidenced by no effect on the number of FSH-dependent oocytes ovulated in immature female rats [24] , and because it appeared to function as a biased antagonist, we reasoned that an effective blockade may be achieved by an FSHR NAM that blocked both arms of the FSHR steroidogenic pathway. To this end, a highthroughput screen identified an FSHR NAM (ADX68692) that blocked both arms of the FSHR steroidogenic pathway. Here we demonstrate that ADX68692 decreased the number of oocytes recovered from ampullae after FSH treatment followed by an ovulatory dose of hCG. Furthermore, a structural analog that had better oral efficacy (ADX68693) but did not inhibit estradiol production was ineffective at inhibiting FSH-induced follicular development.
MATERIALS AND METHODS

Drugs
Recombinant hFSH (Gonal F) was acquired from Merck Serono or from Cell Science. Human pituitary FSH was purified as previously described [13] . Highly purified human urinary FSH was purchased from Cytoshop. The FSHR NAMs ADX68692 (MW 401.44) and ADX68693 (MW 352.42) were prepared by Addex Pharmaceuticals S.A. The chemical structures and formulas are shown in Figure 1 . The specificity of each was determined by Addex Pharmaceuticals: ADX68692 exhibited an IC 50 of 140 nM for hFSHR and 207 nM for the rat FSHR (rFSHR). It had an IC 50 of 804 nM at the human LH receptor (hLHR) and was not active at the human TSH receptor (hTSHR). ADX68693 exhibited inhibition of hFSHR at 104 nM, hLHR at 314 nM, and no activity with hTSHR at 30 lM.
In Vitro Bioassays
The general procedure previously described was followed [30] . In the tissue preparation room in the animal facility, ovaries were dissected to remove integument, fat, and attached tissue and were freed from the bursa using dissecting microscopes. The ovaries were then placed in fresh medium and kept in the CO 2 incubator until all the ovaries were harvested in this manner. Each pair of ovaries, one pair at a time, was punctured with 35 gauge needles until all the large follicles had been punctured. Ovaries were returned to the incubator so that only one pair of ovaries was handled by an operator in atmosphere at one time. After all the ovaries were processed in this way, Petri dishes containing the punctured ovaries were removed from the cell culture procedure room in the animal facility and taken to the laboratory for further manipulation. The cells that had been released by puncturing the ovaries were triturated off the dishes and collected into 50 ml sterile polypropylene tubes. The remaining ovarian tissue was also pooled and transferred to a single tube, and fresh media was added. With a 50 ml pipette, the ovarian tissue was triturated to further release any remaining granulosa cells. The tissue pieces were allowed to settle and then the cell suspension was pooled with the rest of the cells and plated immediately. The granulosa cells were then cultured in 1:1 (v/v) Ham F12:DMEM (Dulbecco-modified Eagle medium) supplemented with 10% chicken serum, and 1 lM testosterone (the substrate for aromatase), in a humidified atmosphere containing 5% CO 2 and 95% air at 378C [31, 32] and used the next day. The production of estradiol in rat granulosa cell cultures begins its rise 24-48 h after FSH treatment and then is highest at 96 h post-FSH treatment [30] . Progesterone production wanes beginning at 72 h.
Granulosa cells (5 3 10 5 cells/culture dish) were washed with warm medium and then preincubated for 15 min at 378C in 0.5 ml medium in the presence of small molecules added to the dish with the incubation continuing for 60 min at 378C. FSH was added to a final concentration of 30 ng/ml. ADX68692 was added at indicated doses ranging from 0.1 to 30 lM. After 72 h of incubation, the medium was removed and heated for 10 min at 908C. Insoluble material in media was removed by centrifugation (15 000 3 g at 48C) for 15 min, and the progesterone and estradiol measured in the supernatant as previously described [33] . 
DIAS ET AL.
Measurement of cAMP
Addex compounds ADX68692 and ADX68693 were tested for their ability to suppress both FSH-induced secreted and intracellular cAMP in primary cultures of rat granulosa cells. Primary cultures of rat granulosa cells were harvested from diethylstilbesterol (DES)-treated rats and plated in 24-well plates. The cells were cultured in DMEM/F12 plus 10% chicken serum, penicillin/streptomycin (P/S), and 6 1 mM 3-isobutyl-1-methylxanthine at 378C and 5% CO 2 for 24 h. Cells were then treated with dimethyl sulfoxide (DMSO) or 30 lM Addex compounds for 1 h in triplicate. After an additional 1 h incubation with purified hFSH (300 ng/well), the culture medium was collected and clarified by centrifugation at 20 000 3 g for 10 min at room temperature. The supernatant was later analyzed by radioimmunoassay (RIA) for secreted cAMP levels. The plates were frozen and thawed (4 cycles) to lyse the cells, and 100% ethanol was added (300 ll/well). These samples were also collected and clarified by centrifugation at 20 000 3 g for 10 min at room temperature. The supernatant from this step was analyzed by RIA to determine intracellular cAMP levels. Accumulation of cAMP was determined by RIA as previously described, and the data are expressed as means and standard errors [34] .
I-hFSH Binding and Internalization
125
I-hFSH binding and internalization studies were performed as previously described [35] .
In Vivo Bioassays
Ovulation induction assay. Animal studies testing FSHR NAM ADX68692 were approved by the Wadsworth Center Institutional Animal Care and Use Committee and assigned protocol no. 06-407. An amendment to this protocol was approved for the administration of compounds via the oral route. Either Wistar Hanover rats or Spague-Dawley rats (Taconic Farms) were provided with standard pelleted diet and water ad libitum and used at the indicated ages.
The ovulation induction assay measures the ability of FSH to recruit and mature follicles that are then induced to ovulate by hCG. Immature female rats 22 days of age were sorted into the experimental groups and given subcutaneous or oral doses of 100.0, 50, 30, 10, and 0 mg/kg of compound twice per day (0900 and 1600 h) for 2 days. Animals were treated with hFSH at the doses indicated provided 1 h after administration of the compound. To induce ovulation of the matured follicles, all the animals received 20 international units (IU) hCG on the afternoon of the second day.
ADX68692 was soluble up to 18.17 mg/ml of polyethylenglcol 400 (PEG400). To include the 100 mg/kg dose, the volume injected was increased to 6 ml/kg. Thus, for 100 mg/kg, ADX68692 was solubilized at 18.17 mg/ml and administered at 6 ml/kg. For 50 mg/kg, compound was solubilized at 9.085 mg/ml and administered at 6 ml/kg. For 30 mg/kg, compound was solubilized at 5.455 mg/ml and administered at 6 ml/kg. Human pituitary FSH was administered as 1 or 2 lg in 100 ll (4 or 8 lg total) sterile saline as indicated. The vehicle for hCG and FSH was phosphate buffered saline (PBS).
On the morning after ovulation induction, rats were anesthetized with isoflurane and then sacrificed by cervical dislocation. The ovaries were removed and placed in cold DMEM/F12 media until all the animals were processed. The ovaries were transferred to an adjacent laboratory within the animal facility and examined under dissecting microscopes. Ovaries exhibiting the presence of ampullas were nicked at the ampulla, and the egg clutch was extruded into PBS and then transferred under oil microdrops. Hyaluronidase (10%) was added to microdrops and when the oocytes settled into a single layer, they were counted. The ovaries were also dissected free of fat, tissue, and the bursa, then placed in media and weighed on a microbalance.
Natural cycles assay. Twenty-eight 3-wk-old Sprague-Dawley female rats were received into the facility and allowed to acclimate for 7 wk in a climatecontrolled room with a 12L:12D regimen (lights on at 0700). Lights were gradually changed over a 1 wk period to correspond to daylight savings time. The average weight of the rats at the beginning of the experiment was 200 6 4.4 g.
Rats were injected subcutaneously with 40 lg of D-Ala6-des Gly10-LH-RH ethylamide (Sigma-Aldrich) to synchronize their estrous cycles [36] . Beginning the next day, and for the duration of the experiment at 0800 h each day, estrous cycle stage was determined by vaginal lavage [37] . The recovered cells were placed on a positively charged Superfrostplus slide (Fisher Scientific) and stained using the hematoxylin and eosin method. The cycle stage was recorded daily for 8 days (two estrous cycles) before beginning treatment with ADX68692. Only rats with consistent 4-day cycles were included in the experiment.
Although ADX68692 can be easily solubilized in PEG400 up to 18 mg/ml, it was found that the animals were having difficulty with acceptance of treatments with oral dosing of PEG400. They were fully and rapidly accommodated to oral dosing with corn oil. Therefore, ADX68692 was sonicated in Mazola brand corn oil at a concentration of 12 mg/ml for the 10 mg/kg body weight treatments and at 30 mg/ml for the 25 mg/kg body weight treatments. The compound was sonicated in a water bath over 2.5 h. Clarification of the mixture was not evident, and it was therefore used as a suspension.
All the animals were treated by oral gavage with corn oil, the vehicle, during the pretreatment phase of the experiment. This allowed us to determine if corn oil treatment regime had an unintended effect on the estrous cycle (not expected), and this also allowed the animals to become accustomed to the oral dosing by gavage. During the treatment phase, the compounds or vehicle were administered twice daily over 12 days (three cycles) and during mating (3 days). A sample of vaginal lavage containing epithelial and immune cells were taken from each rat by depositing 3-5 drops of PBS, pH 7.0, with 20% bovine serum albumin into the vagina with a fire-polished glass Pasteur pipette. The cells were quickly aspirated, and one drop was deposited on a prewarmed Superfrost slide with the remaining drops being added to a corresponding well of a 48-well plate (preloaded with 50 ll/well of PBS). The slides were allowed to dry on a slide warmer and then fixed by immediately placing them into 95% ethanol. Estrous cycle stage determination continued as described above for the duration of the experiment.
Inhibition of FSH action was predicted to affect the pattern of estrous cytology because steroid production would be inhibited. Because the vaginal cytology of normally cycling rats change daily, rats in this experiment that maintained an irregular cycle or persistent diestrus or persistent estrous vaginal cytology were considered to have stopped cycling normally [38, 39] . All the animals were bred on the morning of proestrus as evidenced by the vaginal cytology in the control group. Rats were bred using trio breeding, where one male is placed into a cage with two females on the evening of proestrus. Successful mating was confirmed by the presence of sperm in the vaginal smear. Females were separated from the males by removing them from the males' cages after 3 days. Animals were sacrificed 11 days after the females were removed from the males, and implantation sites in uteri were determined. The uterus and ovaries were removed and fixed in Bouin, and trunk blood was obtained by decapitation. Serum was collected and stored at À208C.
Data Analysis
The concentration-response curves of representative compounds in the presence of EC 80 of FSHR agonist were generated using the GraphPad Prism program (GraphPad Software Inc.). The curves were fitted to a four-parameter logistic equation Y ¼ Basal þ
Maximum ResponseÀBasal 1þ10
ððLogIC 50 ÀXÞ 3 Hill SlopeÞ allowing determination of IC 50 values. Each curve was performed using duplicate sample per data point and 10 concentrations. The concentration-response curves of a selective FSHR agonist in the absence or in the presence of representative compounds of the present invention were also generated using GraphPad Prism program (GraphPad Software Inc.). The curves were fitted to a four-parameter logistic equation Y ¼ Basal þ
ððLogEC 50 ÀXÞ 3 Hill SlopeÞ allowing determination of EC 50 values of the selective FSHR agonist. Each curve was performed using duplicate sample per data point and 10 concentrations.
Animal the experiments were analyzed by a one-way analysis of variance performed using Prism software. Posttests were performed using NeumanKeuls multiple-range comparisons.
RESULTS
Effect of FSHR NAMs on 125 I-hFSH Binding, Internalization, and Induction of cAMP
The FSHR NAM ADX68692 was identified in a highthroughput screen using hFSHR and an Addex Pharmaceuticals S.A. corporate library as previously described [24] . Consistent with the property of allosteric modulation, it was not expected that an FSHR NAM would inhibit binding of 125 IhFSH to its receptor. This hypothesis was tested by determining the effect of ADX68692 on binding of radioiodinated FSH to the hFSHR stably expressed in HEK293 cells [40] . The FSHR NAM ADX68692 did not inhibit the binding of 125 I-hFSH to hFSHR, which was stably expressed in HEK293 cells, but it did increase the binding of 125 I-hFSH approximately threefold (Fig. 2A) . Because of this increased FSHR NEGATIVE ALLOSTERIC MODULATOR binding, it was not possible to calculate the affinity constant. The Hill slope was 1.2 6 0.2 for control and compound, suggesting that there was a change in the capacity for binding not a change in affinity. The IC 50 of FSH inhibition was 38 6 0.03 ng for ADX68692 and 136 6 0.08 ng in control-treated cells. Therefore, it appeared that the mechanism for the observed increase in binding of 125 I-hFSH to its receptor was due to an uncovering of cryptic sites.
Interestingly, the increase in surface-associated FSH did not result in a concomitant increase in amount of cell-associated internalized 125 I-hFSH (Fig. 2B ) although again, it was found that there was an increase (in this case, threefold) of binding at the higher doses of inhibitor. Cell surface and cell-associated (internalized) FSH was determined as previously reported [35] . Thus, FSHR NAM ADX68692 did not inhibit internalization of 125 I-hFSH because comparable amounts of cell-associated (acid resistant) radioactivity were found in cells in the absence or presence of ADX68692 (Fig. 2B) .
Because ADX68692 was identified in a high-throughput screen using hFSHR, it was important to demonstrate that ADX68692 also inhibited cAMP production of the rFSHR because rats were to be used as the in vivo animal model. Indeed, in rat granulosa cells, this was the case as shown in Figure 3 , A and B, ADX68692 blocked both cell-associated and secreted cAMP production in rat granulosa cells. An analog of ADX68692 was prepared that was named I-hFSH was prepared using human urinary FSH. Specific binding was measured by low pH cell surface elution of radiolabeled hFSH as previously described [35] . These binding data were then analyzed using Prism to determine the Hill slope and IC 50 values. B) FSHR NAM ADX68692 does not inhibit internalization of the FSHR/ 125 I-hFSH bound complex. Following the procedures described above, increasing doses of FSHR NAM ADX68692 were preincubated with cells followed by addition of tracer. Following low pH elution of cell surface-bound 125 I-hFSH, internalized 125 I-hFSH was determined (cell associated) by strong base dissolution of the attached cells as previously described [35] . As was observed in A, ADX68692 again engendered an increase in binding consistent with the same results as in A. An additional independent experiment using 30 lM ADX68692 replicated the threefold increase in cell surface binding.
DIAS ET AL.
ADX68693. This compound was found to have a longer halflife by oral administration, remaining in circulation at higher levels for longer periods of time than ADX68692 (data not shown). Therefore, it was of interest to compare ADX68693 in vitro activity to that of ADX68692. It was established that ADX68693 also suppressed FSH-mediated cAMP production in primary cultures of rat granulosa cells (Fig. 3, A and B) .
Effect of FSHR NAMs on FSH-Induced Progesterone Production
The effect of FSHR NAMS ADX68692 and ADX68693 on FSH-induced progesterone production was also determined using primary cultures of rat granulosa cells. These experiments were repeated twice using different primary cell cultures in each experiment. FSH-induced progesterone production was inhibited by ADX68692 (Fig. 4, A and B) . This was the case whether media was collected at 24 or 72 h post-FSH treatment (data not shown). ADX68693 also suppressed FSH-induced progesterone production with a similar efficacy to ADX68692 (Fig. 4, C and D) . At very low doses of compound, there sometimes appeared an increase in production of progesterone compared to the DMSO controls. As a result, the IC 50 was only calculated based on the descending part of the curve. The calculated IC 50 for ADX68692 was consistent over several experiments, usually around 1 lM, and overall, the two compounds appeared to be equally potent in blocking progesterone production.
Effect of FSHR NAMs on FSH-Induced Estradiol Production
Because FSH induces both progesterone and estradiol production, ADX68692 and ADX68693 were also tested with a specific aim of determining if each compound could block estradiol production. Because both compounds were shown to inhibit FSHR-mediated cAMP and progesterone production, it was anticipated that estradiol production would also be inhibited by both ADX68692 and its structural analog ADX68693. Following FSH stimulation of rat granulosa cell cultures in the presence and absence of FSHR NAMs, samples were collected at 72 h and estrogen levels were determined in all the samples (Fig. 4A-D) . The difference in effect of the two structurally related compounds on estrogen production was unexpected. ADX68692 inhibited estradiol production with an IC 50 of 0.82 lM, similar to its efficacy at inhibiting progesterone production (Fig. 4, A and B) . Surprisingly its structural analog ADX68693 augmented the FSH-induced estradiol production (Fig. 4, C and D) but did not have any intrinsic agonist activity. An inflection point at 1 lM compound was observed in both experiments, with FIG. 3. FSHR NAMs ADX68692 and ADX68693 suppress FSH-induced secreted and intracellular cAMP production in primary cultures of rat granulosa cells. The effects of the FSHR NAMs were verified in an additional experiment. The legends top to bottom correspond to the data represented from left to right. Primary cultures of rat granulosa cells were harvested from DES-treated rats and plated in 24-well plates. The cells were cultured in DMEM/F12 plus10% chicken serum, P/S, and 6 1 mM 3-isobutyl-1-methylxanthine at 378C and 5% CO 2 for 24 h. Cells were then treated with DMSO or 30 lM Addex compounds for 1 h. After an additional 1 h incubation with purified hFSH (300 ng/well), the culture medium was collected and clarified by centrifugation at 20 000 3 g for 10 min at room temperature. The supernatant was frozen and analyzed by RIA to determine secreted cAMP levels (A). The cells remaining on the plates were frozen and thawed (4 cycles) to lyse the cells, and 100% ethanol was added (300 ll/well). These samples were also collected and clarified by centrifugation at 20 000 3 g for 10 min at room temperature and frozen until assayed. The supernatant from this step was analyzed by RIA to determine intracellular cAMP levels (B).
FSHR NEGATIVE ALLOSTERIC MODULATOR ADX68693, suggesting that at the IC 50 of receptor inhibition (as measured by progesterone production), the synergistic effect was muted by the antagonistic effect. It is unlikely due to any plating irregularity of cells because the identical wells in which progesterone was measured showed no such effect.
In Vivo Activity of FSHR NAMs
Effect of FSHR NAM ADX68692 on FSH dependent ovarian weight gain and oocytes ovulated. When the animals were treated twice daily for 2 days with 1 lg FSH for 1 h after each dose of 30, 50, and 100 mg/kg ADX68692, there was no effect on ovarian weight gain stimulated by FSH treatment (Fig. 5A) . In contrast the number of FSH-dependent oocytes ovulated was inhibited by ADX68692 at all doses tested (Fig. 5B) . Although the number of oocytes recovered from the ampullae was markedly decreased at the lowest dose tested (30 mg/kg; P . 0.05) the number of oocytes recovered was suppressed at 50 and 100 mg/kg (P , 0.001). One animal in the 30 mg/kg dose group produced oocytes despite the treatment with the FSHR inhibitor. This animal had an almost twofold greater number of oocytes in the ampullae than in the control animals, which were not treated with ADX68692 but were treated with FSH. The effect of the FSHR inhibitor was not consistent as one animal in the 100 mg/kg group and one in the 50 mg/kg group ovulated oocytes. An additional experiment was performed using 2 lg of hFSH per dose, using weight-matched animals, with similar results (data not shown).
In that experiment, ADX68692 treatment again did not have an effect on ovarian weight gain induced by FSH but a statistically significant inhibition of the number of oocytes recovered following ovulation with hCG was observed at all the doses tested. Consistent with first experiment, the 30 mg/kg dose was not as effective as the 50 and 100 mg/kg dose. Two animals had oocytes in their ampullae and two animals did not at that dose level. No oocytes were found in ampullae of any animals at either the 50 or 100 mg/kg doses.
In order to determine if ADX68692 was active by oral route, ADX68692 was administered by gavage in a preliminary experiment and in a dose response study (Fig. 6) . The positive control was PEG (vehicle) gavage with 4 lg FSH/day and the negative control was PEG gavage with PBS (vehicle). As with subcutaneous injection, animals treated orally with ADX68692 did not show a dose-related inhibition of ovarian weight gain (data not shown). Oral administration of ADX68692 showed a dose-related inhibition of the number of FSH-dependent oocytes recovered in the ampullae following treatment with hCG (Fig. 6 ). All the doses of ADX68692 were significantly different from the control treatment (P , 0.05). One animal did have oocytes in its ampullae in the 50 mg/kg dose group, and two animals had oocytes that were ovulated in the 10 mg/ kg group but one of those animals only produced 3 oocytes.
Effect of FSHR NAM ADX68693 on FSH-induced ovarian weight gain and number of oocytes ovulated. Given its superior pharmacokinetic properties compared to ADX68692 (Cmax 1656 6 338 ng/ml v. 1095 6 145 ng/ml, respectively), it was of interest to determine if ADX68693, the structural analog of ADX68692, was more active than D) on FSH-induced progesterone and estradiol production in primary cultures of rat granulosa cells. Primary cultures of rat granulosa cells were harvested from DES-treated rats and plated in 24-well plates. The cells were cultured in DMEM/F12 plus10% chicken serum and P/S at 378C and 5% CO 2 for 24 h. In plates that were to be used for estradiol production, 1 lM testosterone (the substrate for aromatase), was included in the media [30] . Cells were then treated with DMSO or increasing doses of FSHR NAMs as indicated for 1 h. After an additional 72 h incubation with purified hFSH (30 ng/ml), the culture medium was collected and clarified by centrifugation at 20 000 3 g for 10 min at room temperature. The supernatant was later analyzed by RIA to determine secreted steroid levels. The results are representative of replicated experiments.
DIAS ET AL.
ADX68692 in vivo. An initial experiment was carried out using a dose of 100 mg/kg of ADX68693 administered by oral gavage. Unexpectedly, ADX68693 did not decrease the number of FSH-dependent oocytes ovulated. Animals treated with ADX68693 ovulated 24 6 21.4 oocytes per ovary compared to animals treated with PEG400 vehicle 27.4 6 17.5 oocytes per ovary (n ¼ 9). To confirm this, other tests were performed including comparisons with ADX68692 where the compounds were administered by subcutaneous injection. These tests also failed to show that ADX68693 could decrease the number of FSH-dependent oocytes that were ovulated (data not shown).
Effect of ADX68692 on Estrous Cycle, Fertility, and Fecundity of Mature Female Rats ADX68692 was further tested in mature female rats to determine if estrous cycle and fertility would be affected.
Inhibition of FSH action would change the steroid milieu, and it was anticipated that estrous cycles would be disrupted and vaginal cytology which is affected by steroids would be altered [41] . In addition, it was anticipated that ADX68692 would block endogenous FSH action, thereby decreasing the available pool of oocytes that could be ovulated and the number of fetal implantation sites. Ten animals were randomly assigned to a control group and nine animals each were assigned to be tested with 10 and 25 mg/kg of ADX68692.
Effect of ADX68692 on the estrous cycle. Nine out of ten animals in the control group exhibited normal estrous cycles throughout the experimental period (Fig. 7) . One control rat that did not show consistent 4-day cycles throughout the experiment was excluded from the experiment. Treatment with either 25 mg/kg (n ¼ 9) or 10 mg/kg (n ¼ 9) ADX68692 twice daily for 12 days disrupted rat estrous cycles (Fig. 7) . All nine rats in the 10 mg/kg treatment group cycled normally until approximately 8 days posttreatment, when they began to show irregular estrous cycles (Fig. 7 ). An irregular cycle is defined as any deviation from the normal expected pattern of vaginal cytology that would be expected during a 4-day period [41] . The pattern of change from normal varied among the rats, which was not unexpected in an outbred strain of rat such as the one used in this experiment. None of the rats showed continuous estrous or diestrus smears for longer than 4 consecutive days, indicating that their circulating levels of estrogen and progesterone were still changing over time. The nine rats in the 25 mg/kg treatment group showed a similar pattern as rats in the 10 mg/kg group, except that they tended to have comparatively more days in diestrus.
Effect of ADX68692 on fertility and fecundity. Rats treated for 12 days with corn oil or ADX68692 were exposed to males for an additional 3 days with continued treatment. Rat vaginal lavage samples were examined each day of cohabitation with the males to check for sperm or estrous cycle cytology. One rat that did not successfully mate was excluded FIG. 5. A) Effect of administration of ADX68692 (dissolved in PEG; subcutaneously) on ovarian weights. There was no significant difference between the mean ovarian weights of each treatment group (P ¼ 0.08). B) Effect of administration of ADX68692 by subcutaneous injection on number of oocytes recovered in the ampullae. Oocytes were recovered in ampullae of rats (five animals per dose) treated with 1 lg pituitary hFSH for 1 h after each dose of FSHR NAM, and then on the fourth dose of FSH ovulated with 20 IU hCG. Ten ovaries were counted per dose. The data are represented as SEM, and each point is the mean of 10 observations. On average FSH treatment yielded about nine oocytes per ampullae in the absence of FSHR NAM. There was no difference between the average number of oocytes recovered at 0 and 30 mg/kg doses (P . 0.05). At the 50 and 100 mg/kg doses where the average number or oocytes per ampullae was 1.4, there was about an 85% decrease overall of recovered oocytes, which was a highly significant difference (P , 0.001). FSHR NEGATIVE ALLOSTERIC MODULATOR from the results due to loss of weight during the experiment and the presence of a 5-day estrous cycle. One rat out of nine in the control group and two of nine in the 10 mg/kg treatment group did not mate. The rat in the control group did not mate despite the presence of a proestrus vaginal cytology on the day she was introduced into the male's cage. The remaining animals successfully mated, whether or not they had a proestrus smear during the time that they were cohabitating with the males. Seven out of nine animals conceived in the control group, whereas three conceived in the 10 mg/kg group and 5 conceived in the 25 mg/kg group (Table 1) . There was no significant difference in the percentage of animals that conceived (chi square ¼ 4, d.f. ¼ 2, P ¼ 0.1653). Implantation sites were determined for animals that conceived (Fig. 8) . Seven animals in the control group, three animals in the 10 mg/ kg group, and four animals in the 25 mg/kg group conceived. Only one of the control rats that successfully mated did not have implantation sites in the uterus. Four out of seven rats in the 10 mg/kg group and four of nine in the 25 mg/kg group that successfully mated did not have implantation sites. One rat in the 25 mg/kg group only had two implantation sites. Thus overall, if an animal mated and conceived, there was no significant difference in the number of implantation sites per animal that was pregnant between treatment groups suggesting that the 25 mg/kg dose did not lower the number of oocytes that were ovulated in those animals that did breed and conceive (Fig. 8) . There was no discernible pattern of estrous cycle changes when comparing rats with implantation sites to those without in either of the groups.
DISCUSSION
The present studies have identified an FSHR NAM ADX68692 as an effective inhibitor of FSHR-mediated steroidogenesis in vitro. ADX68692 inhibits both progesterone and estradiol production induced by FSH. ADX68692 also blocked the number of ovulated oocytes that were dependent on exogenously administered FSH in immature female rats. Low doses of ADX68692 were orally active in mature female FIG. 7 . Estrous cycles of adult female Sprague-Dawley rats treated with ADX68692 or corn oil. Rats were synchronized with a GNRH antagonist, and corn oil was administered for 8 days (two estrous cycles) twice daily by oral gavage. Then either corn oil or ADX68692 in corn oil was administered for an additional 12 days. The data are graphed as the means of nine animals where the stage of the cycle was ranked as estrus ¼ 4, proestrus ¼ 3, diestrus ¼ 2, and metestrus ¼ 1. (Fig. 7) were exposed to males for 3 days while continuing to receive treatments for those additional 3 days. Mating was determined by sperm in vaginal lavage. Eleven days after confirmed mating, those animals that mated were sacrificed and examined for implantation sites. There was no significant difference in number of implantation sites present in each animal that conceived following mating when compared between treatment groups.
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rats, in terms of disrupting estrus cycles. However higher doses and different dosing regimen or formulations need to be examined to determine if a complete block can be achieved in contrast to the ovulation induction experiments that use immature animals lacking the body fat that mature female rats have. Also in the ovulation induction experiments, timed administration of the small molecule as well as the injection of FSH may afford more control than with cycling animals. In addition, we used lower doses (10 and 25 mg/kg) in order to determine if accumulation over time would ameliorate the need for a high dose so the results may have been more striking if a higher dose was used. If one combines the data for both treatment groups and compares to the controls, it certainly would suggest an effect of FSHR NAM on reducing the number of pregnancies. The absence of effect on implantation sites suggests to us that some animals escape the effects of the small molecules, and if they do, the compounds do not adversely affect embryos or numbers of follicles that develop. These studies also revealed that suppression of both arms of the FSH-induced steroidogenic pathway is essential to block follicular maturation that is required for ovulation of oocytes and potentially achieve contraception. Thus, whereas ADX68692 is orally active in blocking FSH-induced follicular development and therefore the number of oocytes subsequently ovulated in vivo, a structural analog ADX68693 is not active in this regard. ADX68693 inhibited FSH-induced progesterone production but synergized with FSH to increase estradiol production. Because the bioavailability of ADX68693 compared to ADX68692 is not an issue, it seems reasonable to conclude that the in vivo activity of ADX68692 is dependent on its ability to suppress FSH-induced progesterone and estradiol production. Conversely, it may be useful to determine if ADX68693 can be used as a fertility booster, which might be useful in women's natural cycles, alleviating the need for controlled ovarian hyperstimulation in low responders. Alternatively, it may be useful during the perimenopausal period to ameliorate hot flashes and preserve bone by rescuing or boosting the waning ovary.
The estrogen-suppressing activity of ADX68692 seems to rest in the structural characteristics that distinguish it from its analog ADX68693. The main structural difference is the presence of a polar basic pyridyl group in ADX68692 instead of a small lipophilic ethyl substituent in ADX68693. Allosteric modulation of receptor conformational space seems a likely mechanism [29] . For example, ADX68692 increased FSH binding to its receptor approximately two-to threefold, possibly by stabilizing a conformer of the receptor that is not productive for coupling to Gasbc-protein. Interestingly this phenomenon has been reported to occur when FSHR is exposed to a positive allosteric regulator of FSH [42] . In that case the authors concluded that a change in affinity constant was the underpinning factor, causing an increase in binding [42] . Whether the observed increase in binding in the present studies is due to a conformational change that can apparently accommodate more FSH molecules or a change in affinity remains to be determined by more detailed studies. This observation may be explained in light of a new crystal structure of the hFSHR extracellular domain [43] . The new structure unexpectedly revealed that the extracellular domain of hFSHR in the crystal unit cell exists as a trimer with each protomer bound to one heterodimeric FSH molecule. One likely scenario is that in vivo, FSHR exists as a trimer but can only bind one molecule of FSH. An FSHR NAM that perturbs the TM domain may relax the trimer, allowing additional molecules of FSH to bind. This suggests that FSHR may only bind to one molecule of FSH to engage G protein and effectuate nucleotide exchange, leading to dissociation of the heterotrimeric molecule and subsequent activation of adenylate cyclase. The ability to effectuate the adenylate cyclase pathway may be attenuated when the trimeric FSHR opens up to allow binding of two additional molecules of FSH. However, it may be that other pathways may be activated in the trimer phase of the trimer state. A structure of the FSHR TM domain is not available; docking studies using published GPCR structures [44] may yield further insights.
The intriguing finding that ADX68693 suppresses progesterone production but acts differently with regard to estrogen production may be due to how the FSHR couples to its repertoire of G proteins and other downstream effectors, most notably b-arrestin [45] . The observation was timely because of the recent appreciation that receptor-effector complexes persist within cells and continue to signal after the initial burst of cAMP [46] . Thus, functionally selective effects of FSH on its target cells confirm pluridimensionality of gonadotropinsignaling pathways activated by FSH-occupied FSHR, and these are likely highly complex and nonlinear [47, 48] . The selectivity by which the occupied and internalized ligandreceptor signaling complex signals following FSH binding can be modified by G protein receptor kinase (GRK) phosphorylation of FSHR cytoplasmic domains [49] and subsequent interactions with b-arrestins [45] . Putting these data together, one can reasonably suggest that a range of FSHR conformers are stabilized to achieve the pluridimensionality of downstream FSHR effectors [50] . The conformation of the receptor would reasonably be expected to affect which GRK will bind (assuming that GRKs recognize different conformations) and further, that each GRK would imprint a specific barcode on to the cytoplasmic domain of the receptor [51, 52] . Therefore, future studies should try to determine the role of the FSHRinteracting proteins b-arrestins and GRKs as the mechanism that enables selective FSH antagonism at FSHR.
Understanding the basis of selective activation of FSHR could provide for new approaches to in vivo therapies with unprecedented precision and specificity for age-related infertility as well as new approaches to nonsteroidal contraception. The observation that ADX68692 is orally active and that it suppresses estradiol production in vitro suggests that it suppresses estradiol production in vivo as well. If so, then it would be anticipated that ADX68692 would also be useful for ameliorating disease or pain that is exacerbated by estradiol or cancer that is estrogen dependent. In this regard, because endometriosis is an estrogen-dependent disease that affects 5%-15% of women, an FSHR NAM may prove to provide some useful therapy to help alleviate the pain and suffering caused by this sometimes debilitating disease.
